TAURx Submits Extraordinary Application for HMTM as Alzheimer’s Disease Breakthrough
TauRx Pharmaceuticals has submitted a Marketing Authorisation Application (MAA) in the UK for hydromethylthionine mesylate (HMTM), a potential treatment...
Mendel’s AI System Outperforms GPT-4 in Patient Cohort Identification
Mendel, a leader in clinical AI, has announced advancements in its neuro-Symbolic AI system, which automates the identification of...
Breakthrough Med: Epcoritamab Revolutionizes Follicular Lymphoma Treatment
The European Medicines Agency (EMA) has recommended granting marketing authorization for epcoritamab, a monoclonal antibody for treating relapsed or...
Thermo Fisher’s Lab Expansion: A Boon for Kentucky’s Health Research
Thermo Fisher Scientific’s PPD clinical research arm is significantly expanding its presence in Kentucky. The expansion entails a 65,000-square-foot...
COVID-19: Pfizer-BioNTech’s New Omicron Vaccine Receives EU Approval
Pfizer and BioNTech‘s Omicron JN.1-adapted COVID-19 vaccine (COMIRNATY® JN.1) has received a positive recommendation for marketing authorization from the...
QPS Announces New Laboratory Services for Clinical Trials and Cell Therapy
QPS, a prominent global contract research organization, has introduced enhanced laboratory services at its Springfield, Missouri unit. This expansion...
VIR Biotechnology Receives FDA Clearance and Fast Track Designation: Chronic Hepatitis Delta Treatment
The U.S. Food and Drug Administration (FDA) has approved an Investigational New Drug (IND) application and granted Fast Track...
DM199 (Rinvecalinase Alfa) Program Expanded by Diamedica Therapeutics into Preeclampsia
DiaMedica Therapeutics, a biotechnology company, is expanding its clinical development program for DM199 into preeclampsia. Preeclampsia is a severe...
Cybin’s Triumph: Set For Novel Psychiatric Research
Cybin Inc., a biopharmaceutical company focused on developing treatments for mental health disorders, has achieved significant milestones in its...
Merck KGaA Provides Update on Phase III TRILYNX Study in Locally Advanced Head and Neck Cancer
Merck KGaA, a renowned science and technology company, has discontinued its Phase III clinical trials for xevinapant in treating...